Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences stock declined 30% this week following disappointing Q2 results. The company reported adjusted earnings of $0.07 per share and sales of $223 million, both significantly below analyst expectations. Usana announced a $29 million goodwill impairment charge on its Hiya business and revised full-year guidance to expect an $11 million loss instead of a $20-27 million profit. Full-year sales guidance was also lowered from $925-1 billion to $910 million.